azd6370
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00690287)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Hexokinase type IVACTIVATOR
GCK activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3-(2-hydroxy-1-methylethoxy)-n-(1-methyl-1h-pyrazol-3-yl)-5-(4-(methylsulfonyl)phenoxy)benzamide
- azd6370
- azd6370
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00690287 | Phase 1 | Feb 1, 2008 | AstraZeneca, IQVIA |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2008 |
| IQVIA | For profit | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1